Study guide

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance

Key Takeaways Explain This Topic AI

The central compartment ( V 1 V_1 V 1 ​ ) consists of vessel-rich organs (brain, heart, liver, kidneys) and receives ~75% of cardiac output despite representing ~10% of body mass; transfer to shallow ( V 2 V_2 V 2 ​ , muscle) and deep ( V 3 V_3 V 3 ​ , adipose) compartments is governed by microscopic rate constants ( k 12 , k 21 , k 13 , k 31 k_{12}, k_{21}, k_{13}, k_{31} k 12 ​ , k 21 ​ , k 13 ​ , k 31 ​ ) and elimination occurs exclusively from V 1 V_1 V 1 ​ ( k 10 k_{10} k 10 ​ ).

First-order elimination is characterized by a constant fraction of drug cleared per unit time with an exponential decay curve ( t 1 / 2 = 0.693 × V d C L t_{1/2} = \frac{0.693 \times V_d}{CL} t 1/2 ​ = C L 0.693 × V d ​ ​ ), whereas zero-order elimination clears a constant absolute amount per unit time due to enzyme saturation at therapeutic concentrations (e.g., ethanol, phenytoin, high-dose salicylates).

Context-sensitive half-time (CSHT) defines the time required for plasma drug concentration to drop by 50% following cessation of a continuous infusion of a given duration; remifentanil exhibits an invariant CSHT of ~3-4 minutes due to rapid non-specific esterase hydrolysis, whereas fentanyl displays an exponential rise up to hundreds of minutes due to deep compartment redistribution back into plasma.

Target-Controlled Infusion (TCI) systems use mathematical models (e.g., Marsh and Schnider for propofol; Minto for remifentanil) and the rate constant k e 0 k_{e0} k e 0 ​ to align plasma concentration ( C p C_p C p ​ ) with effect-site concentration ( C e C_e C e ​ ), accounting for pharmacodynamic hysteresis and hysteresis lag ( t peak t_{\text{peak}} t peak ​ ).

Last updated: October 2026

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance

Pharmacokinetics describes what the body does to a drug, dictating the time course of its absorption, distribution, metabolism, and elimination. In anaesthetic practice, where intravenous hypnotics, analgesics, and muscle relaxants are titrated rapidly to profound clinical endpoints, a mathematical understanding of multi-compartment behavior, clearance kinetics, and infusion dynamics is indispensable.

1. Multicompartmental Pharmacokinetic Models and Rate Constants

Classic pharmacokinetic models simplify physiological tissues into distinct theoretical compartments based on perfusion and drug uptake characteristics. While single-compartment models assume instantaneous uniform mixing throughout the body, most anaesthetic agents exhibit multi-compartmental disposition best represented by two- or three-compartment mammillary models. +-------------------------------+

  • | Shallow Peripheral (V2) |
  • | Muscle, skin, viscera |
  • +-------------------------------+
  • ^ |
  • k12 | | k21
  • | v
  • +-------------+ +-------------------------------+
  • | IV Bolus / | ---> | Central Compartment (V1) | ---> k10 (Elimination)
  • | Infusion | | Vessel-rich group: brain, |
  • +-------------+ | heart, liver, kidneys, lungs |
  • +-------------------------------+
  • ^ |
  • k31 | | k13
  • | v
  • +-------------------------------+
  • | Deep Peripheral (V3) |
  • | Adipose tissue, bone, poorly |
  • | perfused connective tissues |
  • +-------------------------------+
  • Compartment Characteristics and Perfusion Groups

Central Compartment ( V 1 V_1 V 1 ​ ): Comprises the blood volume and the Vessel-Rich Group (VRG) : brain, heart, liver, kidneys, and lungs. Although the VRG constitutes only ~10% of total body mass, it receives approximately 75% of resting cardiac output. Consequently, intravenous drugs rapidly equilibrate with V 1 V_1 V 1 ​ , yielding the initial peak plasma concentration ( C 0 C_0 C 0 ​ ).

Rapid/Shallow Peripheral Compartment ( V 2 V_2 V 2 ​ ): Comprises the Muscle Group : skeletal muscle, skin, and splanchnic viscera. This group represents ~50% of body mass and receives ~19% of cardiac output. It acts as an intermediate reservoir during the early redistribution phase.

Slow/Deep Peripheral Compartment ( V 3 V_3 V 3 ​ ): Comprises the Fat Group and Vessel-Poor Group (VPG) : adipose tissue, bone, cartilage, and tendons. These tissues account for ~20-40% of body mass but receive only ~6% of cardiac output. Highly lipophilic anaesthetics accumulate extensively in V 3 V_3 V 3 ​ during prolonged infusions.

Microscopic Rate Constants and Differential Equations

Transfer between compartments is described by first-order microscopic rate constants ( k i j k_{ij} k ij ​ ), representing the fractional transfer of drug from compartment i i i to compartment j j j per unit time (expressed in min − 1 \text{min}^{-1} min − 1 ):

k 12 k_{12} k 12 ​ : rate constant of drug movement from central ( V 1 V_1 V 1 ​ ) to shallow peripheral ( V 2 V_2 V 2 ​ )

k 21 k_{21} k 21 ​ : rate constant of drug movement from shallow peripheral ( V 2 V_2 V 2 ​ ) back to central ( V 1 V_1 V 1 ​ )

k 13 k_{13} k 13 ​ : rate constant of drug movement from central ( V 1 V_1 V 1 ​ ) to deep peripheral ( V 3 V_3 V 3 ​ )

k 31 k_{31} k 31 ​ : rate constant of drug movement from deep peripheral ( V 3 V_3 V 3 ​ ) back to central ( V 1 V_1 V 1 ​ )

k 10 k_{10} k 10 ​ : rate constant of irreversible systemic elimination directly from the central compartment ( V 1 V_1 V 1 ​ )

The differential equations defining drug mass ( x 1 , x 2 , x 3 x_1, x_2, x_3 x 1 ​ , x 2 ​ , x 3 ​ ) over time are: d x 1 d t = − ( k 10 + k 12 + k 13 ) x 1 + k 21 x 2 + k 31 x 3 + Input ( t ) \frac{dx_1}{dt} = -(k_{10} + k_{12} + k_{13})x_1 + k_{21}x_2 + k_{31}x_3 + \text{Input}(t) d t d x 1 ​ ​ = − ( k 10 ​ + k 12 ​ + k 13 ​ ) x 1 ​ + k 21 ​ x 2 ​ + k 31 ​ x 3 ​ + Input ( t ) d x 2 d t = k 12 x 1 − k 21 x 2 \frac{dx_2}{dt} = k_{12}x_1 - k_{21}x_2 d t d x 2 ​ ​ = k 12 ​ x 1 ​ − k 21 ​ x 2 ​ d x 3 d t = k 13 x 1 − k 31 x 3 \frac{dx_3}{dt} = k_{13}x_1 - k_{31}x_3 d t d x 3 ​ ​ = k 13 ​ x 1 ​ − k 31 ​ x 3 ​

Following an intravenous bolus injection, plasma concentration demonstrates a tri-exponential decline characterized by three distinct mathematical phases: C p ( t ) = A e − α t + B e − β t + C e − γ t C_p(t) = A e^{-\alpha t} + B e^{-\beta t} + C e^{-\gamma t} C p ​ ( t ) = A e − α t + B e − βt + C e − γ t

α \alpha α -Phase (Rapid Distribution): Dominated by rapid mixing within V 1 V_1 V 1 ​ and net transfer into shallow peripheral tissues ( V 2 V_2 V 2 ​ ). This accounts for the rapid termination of clinical effect after a single induction bolus of propofol or thiopental.

β \beta β -Phase (Slow Distribution / Redistribution): Reflects continued redistribution into deep tissues ( V 3 V_3 V 3 ​ ) alongside concurrent metabolic clearance.

γ \gamma γ -Phase (Terminal Elimination): Represents the return of drug from poorly perfused peripheral compartments back to V 1 V_1 V 1 ​ , where it is cleared by elimination organs. The slope is governed by the terminal elimination rate constant (often denoted β \beta β in two-compartment and γ \gamma γ in three-compartment systems).

2. Volumes of Distribution: Physiological Determinants and Steady State

The volume of distribution ( V d V_d V d ​ ) is a theoretical, apparent parameter that relates the total mass of drug in the body ( A body A_{\text{body}} A body ​ ) to its concentration in plasma ( C p C_p C p ​ ): V d = A body C p V_d = \frac{A_{\text{body}}}{C_p} V d ​ = C p ​ A body ​ ​

V d V_d V d ​ does not correspond to an actual anatomical fluid space; rather, it reflects the extent of tissue uptake relative to vascular retention.

Mathematical Subtypes of Distribution Volume

Initial Volume of Distribution ( V 1 V_1 V 1 ​ or V initial V_{\text{initial}} V initial ​ ): The apparent volume immediately after intravenous administration before distribution occurs: V 1 = Dose C 0 V_1 = \frac{\text{Dose}}{C_0} V 1 ​ = C 0 ​ Dose ​ . For propofol, V 1 V_1 V 1 ​ is typically 15-30 L (~0.2-0.4 L/kg).

Steady-State Volume of Distribution ( V d , ss V_{d,\text{ss}} V d , ss ​ ): The sum of the apparent volumes of all compartments when drug concentrations in all tissues are in thermodynamic equilibrium with plasma: V d , ss = V 1 + V 2 + V 3 V_{d,\text{ss}} = V_1 + V_2 + V_3 V d , ss ​ = V 1 ​ + V 2 ​ + V 3 ​ . It is independent of elimination rate and best reflects total body storage capacity at steady state.

Volume of Distribution during Elimination Phase ( V d , β V_{d,\beta} V d , β ​ or V d , area V_{d,\text{area}} V d , area ​ ): Calculated from systemic clearance and the terminal elimination rate constant: V d , β = C L β V_{d,\beta} = \frac{CL}{\beta} V d , β ​ = β C L ​ . Because active elimination occurs continuously during the distribution phase, V d , β V_{d,\beta} V d , β ​ is always larger than V d , ss V_{d,\text{ss}} V d , ss ​ .

Physiological Determinant Influence on Volume of Distribution Clinical Examples

Lipid Solubility Highly lipophilic drugs cross lipid bilayers readily and partition into adipose tissue, creating massive V d V_d V d ​ Propofol ( V d , ss ≈ 2 − 10 L/kg V_{d,\text{ss}} \approx 2-10\text{ L/kg} V d , ss ​ ≈ 2 − 10 L/kg ), Fentanyl ( V d , ss ≈ 4 L/kg V_{d,\text{ss}} \approx 4\text{ L/kg} V d , ss ​ ≈ 4 L/kg )

Molecular Weight Large macromolecules remain trapped in vascular space, yielding small V d V_d V d ​ Heparin ( V d ≈ 0.05 − 0.1 L/kg V_d \approx 0.05-0.1\text{ L/kg} V d ​ ≈ 0.05 − 0.1 L/kg ), Sugammadex ( V d ≈ 0.1 − 0.2 L/kg V_d \approx 0.1-0.2\text{ L/kg} V d ​ ≈ 0.1 − 0.2 L/kg )

Ionization & pKa Un-ionized fractions cross lipid membranes; ionized molecules remain sequestered in aqueous compartments Rocuronium (quaternary amine, highly ionized at physiological pH → V d ≈ 0.2 L/kg \rightarrow V_d \approx 0.2\text{ L/kg} → V d ​ ≈ 0.2 L/kg )

Plasma Protein Binding High binding to circulating proteins sequesters drug intravascularly, limiting V d V_d V d ​ Warfarin (99% bound to albumin → V d ≈ 0.14 L/kg \rightarrow V_d \approx 0.14\text{ L/kg} → V d ​ ≈ 0.14 L/kg )

Tissue Protein Binding High binding to intracellular structures draws drug out of plasma, expanding V d V_d V d ​ Digoxin (binds myocardial Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase → V d ≈ 5 − 7 L/kg \rightarrow V_d \approx 5-7\text{ L/kg} → V d ​ ≈ 5 − 7 L/kg )

Clinical Trap: Acidic anaesthetic drugs (propofol, thiopental, etomidate, NSAIDs) bind primarily to albumin , whereas basic drugs (lidocaine, bupivacaine, alfentanil, sufentanil) bind predominantly to α 1 \alpha_1 α 1 ​ -acid glycoprotein (AAG) . In severe malnutrition, hepatic cirrhosis, nephrotic syndrome, or critical illness, serum albumin drops precipitously. This increases the unbound, pharmacologically active free fraction ( f u f_u f u ​ ) of acidic drugs, predisposing patients to exaggerated clinical effects and toxicity unless bolus doses are reduced.

3. Clearance Mechanics: Systemic, Hepatic, and Renal Elimination

Clearance ( C L CL C L ) is the volume of blood or plasma completely cleared of drug per unit time (expressed in mL/min \text{mL/min} mL/min or L/h \text{L/h} L/h ). Systemic clearance is additive across clearing organs: C L systemic = C L hepatic + C L renal + C L pulmonary + C L other CL_{\text{systemic}} = CL_{\text{hepatic}} + CL_{\text{renal}} + CL_{\text{pulmonary}} + CL_{\text{other}} C L systemic ​ = C L hepatic ​ + C L renal ​ + C L pulmonary ​ + C L other ​

Clearance relates the rate of drug elimination directly to plasma concentration, and can be derived from the area under the plasma concentration-time curve (AUC): C L = Rate of Elimination C p = k 10 × V 1 = Dose AUC CL = \frac{\text{Rate of Elimination}}{C_p} = k_{10} \times V_1 = \frac{\text{Dose}}{\text{AUC}} C L = C p ​ Rate of Elimination ​ = k 10 ​ × V 1 ​ = AUC Dose ​

Hepatic Clearance and Extraction Ratio

Hepatic clearance ( C L H CL_H C L H ​ ) depends on total hepatic blood flow ( Q H ≈ 1.5 L/min Q_H \approx 1.5\text{ L/min} Q H ​ ≈ 1.5 L/min , ~25% of cardiac output) and the hepatic extraction ratio ( E H E_H E H ​ ): C L H = Q H × E H = Q H × ( C in − C out C in ) CL_H = Q_H \times E_H = Q_H \times \left(\frac{C_{\text{in}} - C_{\text{out}}}{C_{\text{in}}}\right) C L H ​ = Q H ​ × E H ​ = Q H ​ × ( C in ​ C in ​ − C out ​ ​ ) where C in C_{\text{in}} C in ​ and C out C_{\text{out}} C out ​ represent drug concentrations entering (portal vein and hepatic artery) and leaving (hepatic vein) the liver. High Extraction Drugs (EH > 0.7) Low Extraction Drugs (EH < 0.3)

  • Clearance = Perfusion-limited - Clearance = Capacity-limited
  • CL_H ~ Q_H - CL_H ~ f_u x CL_intrinsic
  • Sensitive to changes in blood flow - Sensitive to enzyme induction/inhibition
  • Examples: Propofol, Fentanyl, - Examples: Thiopental, Diazepam,
  • Etomidate, Ketamine, Lidocaine Rocuronium, Phenytoin

High Extraction Ratio Drugs ( E H > 0.7 E_H > 0.7 E H ​ > 0.7 ): The liver has massive enzymatic reserve; clearance is rate-limited strictly by hepatic blood flow ( flow-dependent clearance ). Decreases in cardiac output, hypovolemia, β \beta β -blockade, or portosystemic shunting substantially decrease drug clearance. Conversely, competitive enzyme inhibition has little impact.

Low Extraction Ratio Drugs ( E H < 0.3 E_H < 0.3 E H ​ < 0.3 ): The liver clears only a small fraction of drug per pass; clearance is rate-limited by intrinsic metabolic enzyme activity ( C L int CL_{\text{int}} C L int ​ ) and unbound fraction ( f u f_u f u ​ ) ( capacity-limited clearance ). Changes in hepatic blood flow have minimal impact, whereas enzyme induction (rifampin, carbamazepine) or enzyme inhibition (cimetidine, ketoconazole) dramatically alters systemic clearance.

Renal Clearance

Renal clearance ( C L R CL_R C L R ​ ) represents the net outcome of three distinct processes: C L R = ( Filtration + Secretion ) − Reabsorption CL_R = (\text{Filtration} + \text{Secretion}) - \text{Reabsorption} C L R ​ = ( Filtration + Secretion ) − Reabsorption

Glomerular Filtration: Clears free, unbound drug ( G F R × f u GFR \times f_u GFR × f u ​ ). Protein-bound fractions cannot cross the glomerular capillary fenestrations.

Active Tubular Secretion: Occurs in the proximal tubule via organic anion transporters (OATs) and organic cation transporters (OCTs). Carrier-mediated transport can clear both free and weakly protein-bound drug.

Passive Tubular Reabsorption: Occurs in distal tubules. Lipophilic, un-ionized molecules diffuse passively down concentration gradients back into peritubular capillaries. Renal excretion of weak acids (e.g., phenobarbital, salicylates) is markedly accelerated by urine alkalinization (administering NaHCO 3 \text{NaHCO}_3 NaHCO 3 ​ to raise urine pH above the drug's pKa, trapping the ionized species in the tubular lumen).

4. Elimination Kinetics: First-Order vs Zero-Order Dynamics

The fundamental distinction between first-order and zero-order kinetics is governed by the saturation status of metabolic enzymes and transport systems, mathematically defined by the Michaelis-Menten equation : Rate of Elimination = − d C d t = V max ⁡ × C K m + C \text{Rate of Elimination} = -\frac{dC}{dt} = \frac{V_{\max} \times C}{K_m + C} Rate of Elimination = − d t d C ​ = K m ​ + C V m a x ​ × C ​ where V max ⁡ V_{\max} V m a x ​ is the maximal velocity of enzymatic elimination and K m K_m K m ​ is the Michaelis constant (substrate concentration at which the reaction velocity is half V max ⁡ V_{\max} V m a x ​ ).

Parameter First-Order Elimination Zero-Order Elimination

Substrate Concentration C ≪ K m C \ll K_m C ≪ K m ​ (enzymes operate well below saturation) C ≫ K m C \gg K_m C ≫ K m ​ (enzymes operating at maximal capacity, saturated)

Elimination Rate Proportional to concentration: d C d t = − k × C \frac{dC}{dt} = -k \times C d t d C ​ = − k × C Constant mass per unit time: d C d t = − k 0 \frac{dC}{dt} = -k_0 d t d C ​ = − k 0 ​

Fraction Cleared per Time Constant fraction cleared per unit time Variable fraction (decreases as dose increases)

Plasma Clearance ( C L CL C L ) Constant, independent of dose or concentration Decreases progressively with increasing concentration

Elimination Half-Life ( t 1 / 2 t_{1/2} t 1/2 ​ ) Constant , independent of dose: t 1 / 2 = 0.693 × V d C L t_{1/2} = \frac{0.693 \times V_d}{CL} t 1/2 ​ = C L 0.693 × V d ​ ​ Variable ; prolongs as dose and concentration increase

Semi-Logarithmic Plot Straight, linear decline over time Downward curvilinear (steepening curve over time)

Clinical Examples Propofol, remifentanil, fentanyl, neuromuscular blockers (standard doses) Ethanol (~10-15 g/h), Phenytoin , High-dose Salicylates , Thiopental (massive/infusion doses)

Clinical Pearl: Thiopental obeys linear, first-order kinetics at standard single induction doses (3-5 mg/kg) because plasma concentrations remain below metabolic saturation. However, during continuous infusions for refractory status epilepticus or intracranial hypertension, metabolic capacity of hepatic CYP enzymes becomes completely overwhelmed. Thiopental shifts to zero-order elimination, its clearance collapses, and its context-sensitive half-time extends to several days, predisposing patients to prolonged coma.

5. Context-Sensitive Half-Time (CSHT) and Redistribution Dynamics

The elimination half-life ( t 1 / 2 β t_{1/2\beta} t 1/2 β ​ ) represents the time required for plasma concentration to drop by 50% during the terminal elimination phase, once complete equilibrium throughout all body compartments has been achieved. Because anaesthetic infusions are stopped long before full steady-state equilibrium with deep adipose reservoirs occurs, t 1 / 2 β t_{1/2\beta} t 1/2 β ​ notoriously fails to predict the recovery profile.

Definition of Context-Sensitive Half-Time

Context-Sensitive Half-Time (CSHT) is defined as the time required for the central plasma drug concentration to decrease by 50% following termination of a continuous intravenous infusion of a specified duration (the "context"). CSHT (min)

  • ^
  • 300| ... Fentanyl
  • 250| ....''
  • 200| ...-''
  • 150| ....--'
  • 100| ....--'
  • 50| -------------..--------------------------- Sufentanil / Alfentanil
  • 25| ------------------------------------------ Propofol
  • 4| ========================================== Remifentanil (~3-4 min invariant)
  • 0+-------------------------------------------->
  • 0 1 2 3 4 5 6 7 8 Infusion Duration (Hours)
  • Pharmacokinetic Mechanisms Across Key Intravenous Agents

Remifentanil: Possesses an ester linkage that is rapidly cleaved by non-specific blood and tissue esterases. Its metabolic clearance is exceptionally high (~40 mL/kg/min), far exceeding hepatic blood flow. Because termination of effect is governed by relentless enzymatic destruction rather than redistribution, remifentanil's CSHT is invariant at ~3 to 4 minutes , regardless of whether the infusion runs for 15 minutes or 12 hours.

Propofol: Exhibits high metabolic clearance ( C L ≈ 20 − 30 mL/kg/min CL \approx 20-30\text{ mL/kg/min} C L ≈ 20 − 30 mL/kg/min ) combined with rapid transfer into peripheral tissues. For infusions lasting under 2-3 hours, redistribution into V 2 V_2 V 2 ​ and V 3 V_3 V 3 ​ keeps CSHT low (~10-15 minutes). With prolonged infusions (>6-8 hours), deep tissue compartments approach saturation, and CSHT rises moderately to ~30-40 minutes.

Fentanyl: Highly lipophilic with a large steady-state volume of distribution ( V d , ss ≈ 4 L/kg V_{d,\text{ss}} \approx 4\text{ L/kg} V d , ss ​ ≈ 4 L/kg ) and modest clearance ( C L ≈ 10 − 15 mL/kg/min CL \approx 10-15\text{ mL/kg/min} C L ≈ 10 − 15 mL/kg/min ). Following a single bolus, awakening occurs within 10-15 minutes via redistribution into muscle and fat. However, during an infusion, deep peripheral reservoirs fill completely. Upon stopping an infusion that has lasted >2 hours, the concentration gradient reverses: drug diffuses back from saturated tissues into plasma, counteracting metabolic elimination. The CSHT rises exponentially, reaching 200 to 300 minutes after a 4- to 6-hour infusion.

Sufentanil vs Alfentanil Crossover: For infusions lasting less than 7-8 hours, sufentanil exhibits a shorter CSHT than alfentanil because its higher clearance and greater lipid solubility allow more effective peripheral buffering. Only during ultra-prolonged infusions (>8 hours) does sufentanil's accumulation in deep fat reverse this advantage, at which point alfentanil's smaller V d , ss V_{d,\text{ss}} V d , ss ​ results in a lower CSHT.

6. Target-Controlled Infusion (TCI) and Effect-Site Equilibration

Target-Controlled Infusion (TCI) utilizes microprocessor-driven syringe pumps programmed with multi-compartmental pharmacokinetic and pharmacodynamic models. By continuously calculating compartmental transfers and systemic elimination, the pump administers a variable-rate infusion (the BET scheme: Bolus, Elimination, Transfer ) to maintain a user-selected target concentration.

Effect-Site Targeting and the Rate Constant k e 0 k_{e0} k e 0 ​

The clinical effect of an intravenous anaesthetic is determined not by its concentration in plasma ( C p C_p C p ​ ), but by its concentration at its receptor site in the central nervous system: the effect-site concentration ( C e C_e C e ​ ) . Because the blood-brain barrier and tissue diffusion introduce a physical delay, changes in C e C_e C e ​ lag behind changes in C p C_p C p ​ . This temporal lag between drug concentration and clinical effect is termed hysteresis .

To model this lag, an apparent effect-site compartment ( V e V_e V e ​ ) with negligible volume is coupled to the central compartment. Transfer is defined by the rate constant k e 0 k_{e0} k e 0 ​ : d C e d t = k e 0 × ( C p − C e ) \frac{dC_e}{dt} = k_{e0} \times (C_p - C_e) d t d C e ​ ​ = k e 0 ​ × ( C p ​ − C e ​ )

The rate constant k e 0 k_{e0} k e 0 ​ represents the rate of elimination from the effect-site compartment, governing the equilibration half-life ( t 1 / 2 , k e 0 = 0.693 k e 0 t_{1/2,k_{e0}} = \frac{0.693}{k_{e0}} t 1/2 , k e 0 ​ ​ = k e 0 ​ 0.693 ​ ).

The time to peak effect ( t peak t_{\text{peak}} t peak ​ ) following a rapid bolus is inversely related to k e 0 k_{e0} k e 0 ​ : t peak = ln ⁡ ( k e 0 / α ) k e 0 − α t_{\text{peak}} = \frac{\ln(k_{e0}/\alpha)}{k_{e0} - \alpha} t peak ​ = k e 0 ​ − α l n ( k e 0 ​ / α ) ​

Drugs with a large k e 0 k_{e0} k e 0 ​ (e.g., remifentanil k e 0 ≈ 0.595 min − 1 k_{e0} \approx 0.595\text{ min}^{-1} k e 0 ​ ≈ 0.595 min − 1 , alfentanil k e 0 ≈ 0.77 min − 1 k_{e0} \approx 0.77\text{ min}^{-1} k e 0 ​ ≈ 0.77 min − 1 ) equilibrate rapidly with the brain ( t peak ≈ 1 − 1.5 min t_{\text{peak}} \approx 1-1.5\text{ min} t peak ​ ≈ 1 − 1.5 min ), whereas drugs with a small k e 0 k_{e0} k e 0 ​ (e.g., midazolam k e 0 ≈ 0.05 − 0.1 min − 1 k_{e0} \approx 0.05-0.1\text{ min}^{-1} k e 0 ​ ≈ 0.05 − 0.1 min − 1 ) demonstrate marked hysteresis ( t peak ≈ 3 − 5 min t_{\text{peak}} \approx 3-5\text{ min} t peak ​ ≈ 3 − 5 min ).

Propofol Models: Marsh vs Schnider

  • Model Parameter Marsh Model Schnider Model
  • Patient Covariates Weight only Age, Weight, Height, Lean Body Mass (LBM)

Central Volume ( V 1 V_1 V 1 ​ ) Proportional to weight: V 1 = 0.228 L/kg V_1 = 0.228\text{ L/kg} V 1 ​ = 0.228 L/kg (e.g., 16 L in 70 kg adult) Fixed volume : V 1 = 4.27 L V_1 = 4.27\text{ L} V 1 ​ = 4.27 L (independent of patient size)

Peripheral Volumes V 2 = 0.463 L/kg V_2 = 0.463\text{ L/kg} V 2 ​ = 0.463 L/kg , V 3 = 2.893 L/kg V_3 = 2.893\text{ L/kg} V 3 ​ = 2.893 L/kg V 2 = 18.9 − 0.391 ( age − 53 ) V_2 = 18.9 - 0.391(\text{age} - 53) V 2 ​ = 18.9 − 0.391 ( age − 53 ) L (falls with age); V 3 V_3 V 3 ​ fixed at 238 L

Elimination Rate ( k 10 k_{10} k 10 ​ ) Fixed: k 10 = 0.119 min − 1 k_{10} = 0.119\text{ min}^{-1} k 10 ​ = 0.119 min − 1 Calculated from weight, lean body mass and height (not age): k 10 = 0.443 + 0.0107 ( weight − 77 ) − 0.0159 ( LBM − 59 ) + 0.0062 ( height − 177 ) k_{10} = 0.443 + 0.0107(\text{weight}-77) - 0.0159(\text{LBM}-59) + 0.0062(\text{height}-177) k 10 ​ = 0.443 + 0.0107 ( weight − 77 ) − 0.0159 ( LBM − 59 ) + 0.0062 ( height − 177 ) ; age acts through V 2 V_2 V 2 ​ and the rapid intercompartmental clearance

k e 0 k_{e0} k e 0 ​ Rate Constant Historically fixed at 0.26 min − 1 0.26\text{ min}^{-1} 0.26 min − 1 (slow); modified Marsh uses 1.2 min − 1 1.2\text{ min}^{-1} 1.2 min − 1 Fixed at 0.456 min − 1 0.456\text{ min}^{-1} 0.456 min − 1 ( t peak ≈ 1.6 min t_{\text{peak}} \approx 1.6\text{ min} t peak ​ ≈ 1.6 min )

Targeting Mode Originally validated for Plasma targeting ( C p C_p C p ​ ) Designed specifically for Effect-site targeting ( C e C_e C e ​ )

Induction Bolus Dynamics Large initial bolus because V 1 V_1 V 1 ​ is calculated as 16 L in a 70 kg patient Smaller initial bolus because V 1 V_1 V 1 ​ is only 4.27 L; safer in elderly patients

Remifentanil: The Minto Model

The Minto model is the universal standard for remifentanil TCI. It incorporates age, sex, weight, and height to compute Lean Body Mass (LBM via the James formula). Crucially, the Minto model adjusts for the progressive decline in central volume ( V 1 V_1 V 1 ​ ) and systemic clearance that occurs with aging:

V 1 V_1 V 1 ​ decreases from about 5.5 L in a 20-year-old to about 4.3 L in an 80-year-old (for a lean body mass of 55 kg).

Clearance decreases from about 2.9 L/min to about 1.9 L/min over the same age span.

The rate constant k e 0 k_{e0} k e 0 ​ declines with age: k e 0 = 0.595 − 0.007 × ( age − 40 ) k_{e0} = 0.595 - 0.007 \times (\text{age} - 40) k e 0 ​ = 0.595 − 0.007 × ( age − 40 ) .

Clinical Trap with LBM in Morbid Obesity: The James formula for LBM relies on height and weight. In severely obese women (BMI above about 36 kg/m 2 36\text{ kg/m}^2 36 kg/m 2 ) and men (BMI above about 43 kg/m 2 43\text{ kg/m}^2 43 kg/m 2 ), the formula paradoxically calculates a declining LBM as weight increases, causing the TCI pump to deliver inappropriately small doses. In morbidly obese patients, TCI models should be programmed using adjusted body weight or newer allometric models (such as the Eleveld model) to avoid intraoperative awareness.